Durable response to Olaparib in EGFR and somatic BRCA2-mutated lung adenocarcinoma with leptomeningeal metastases: a case report.
Saved in:
| Title: | Durable response to Olaparib in EGFR and somatic BRCA2-mutated lung adenocarcinoma with leptomeningeal metastases: a case report. |
|---|---|
| Authors: | Hou FF; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.; Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China., Liu LR; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.; Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China., Zhao WJ; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China., Qu YC; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.; Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China., Zhou R; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.; Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China., Wang TL; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China., Ye YS; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.; Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China., Chai XS; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.; Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China., Zhang HB; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.; Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China.; Guangdong-Hong Kong-Macau Joint Laboratory on Chinese Medicine and Immune Disease Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Mar 20; Vol. 15, pp. 1512886. Date of Electronic Publication: 2025 Mar 20 (Print Publication: 2025). |
| Publication Type: | Case Reports; Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2025.1512886 |
